(PDF) P1.01-58 Variants Distribution and Heterogeneity of

P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.614

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P071 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

Cancer Research

English

The Activity, Safety, and Evolving Role of Brigatinib in Patients With ALK-rearranged Non-Small Cell Lung Cancers

OncoTargets and Therapy

English

P1.01-78 the Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Multidisciplinary

English

P1.01-61 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-07 CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English